Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
Open Access
- 25 December 2013
- journal article
- review article
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2013, 1-6
- https://doi.org/10.1155/2013/493138
Abstract
Five years ago, we reported the identification and characterization of several regulatory T-cell epitopes (now called Tregitopes) that were discovered in the heavy and light chains of IgG (De Groot et al. Blood, 2008). When added ex vivo to human PBMCs, these Tregitopes activated regulatory T cells (Tregs), increased expression of the transcription factor FoxP3, and induced IL-10 expression in CD4+T cells. We have now shown that coadministration of the Tregitopes in vivo, in a number of different murine models of autoimmune disease, can suppress immune responses to antigen in an antigen-specific manner, and that this response is mediated by Tregs. In addition we have shown that, although these are generally promiscuous epitopes, the activity of individual Tregitope peptides is restricted by HLA. In this brief report, we provide an overview of the effects of Tregitopes in vivo, discuss potential applications, and suggest that Tregitopes may represent one of the “active pharmaceutical ingredients” of IVIg. Tregitope applications may include any of the autoimmune diseases that are currently treated almost exclusively with intravenous immunoglobulin G (IVIG), such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN), as well as gene therapy and allergy where Tregitopes may provide a means of inducing antigen-specific tolerance.Keywords
This publication has 47 references indexed in Scilit:
- Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per seJournal of Leukocyte Biology, 2013
- Tregitope update: Mechanism of action parallels IVIgAutoimmunity Reviews, 2013
- Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantationExpert Review of Clinical Immunology, 2011
- Intravenous immunoglobulins – understanding properties and mechanismsClinical and Experimental Immunology, 2009
- Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): Immunomodulation of gene expressionJournal of Autoimmunity, 2009
- B Cells Induce Tolerance by Presenting Endogenous Peptide-IgG on MHC Class II Molecules via an IFN-γ-Inducible Lysosomal Thiol Reductase-Dependent PathwayThe Journal of Immunology, 2008
- Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive FunctionThe Journal of Immunology, 2007
- Natural versus adaptive regulatory T cellsNature Reviews Immunology, 2003
- In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment.International Immunology, 2002
- Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor functionEuropean Journal of Immunology, 1986